Cargando…

Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide

It has been reported that lipopeptides can be used to elicit cytotoxic T lymphocyte (CTL) responses against viral diseases and cancer. In our previous study, we determined that mono-palmitoylated peptides can enhance anti-tumor responses in the absence of adjuvant activity. To investigate whether di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Kuan-Yin, Song, Ying-Chyi, Chen, I-Hua, Chong, Pele, Liu, Shih-Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514138/ https://www.ncbi.nlm.nih.gov/pubmed/25483652 http://dx.doi.org/10.4161/hv.29275

Ejemplares similares

A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms
por: Song, Ying-Chyi, et al.
Publicado: (2015)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue
por: Corogeanu, Diana, et al.
Publicado: (2023)

A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages
por: Feng, Yanxian, et al.
Publicado: (2019)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy
por: Chang, Li-Sheng, et al.
Publicado: (2014)

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
por: Vo, Manh-Cuong, et al.
Publicado: (2015)

A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population
por: Wu, Chiao-Chieh, et al.
Publicado: (2016)

Toll-like receptors and their role in carcinogenesis and anti-tumor treatment
por: Wolska, Anna, et al.
Publicado: (2008)

Immunomodulatory Response of Toll-like Receptor Ligand–Peptide Conjugates in Food Allergy
por: Losada Méndez, Jorge, et al.
Publicado: (2021)

Conjugation of a Toll‐Like Receptor Agonist to Glycans of an HIV Native‐Like Envelope Trimer Preserves Neutralization Epitopes
por: Li, Zeshi, et al.
Publicado: (2022)

PPAR Gamma agonists regulate tobacco smoke-induced toll like receptor 4 expression in alveolar macrophages
por: Yin, Yan, et al.
Publicado: (2014)

Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
por: Yang, Yang, et al.
Publicado: (2022)

Expression of Toll-Like Receptors on Breast Tumors: Taking a Toll on Tumor Microenvironment
por: Bhattacharya, Debika, et al.
Publicado: (2012)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists
por: Debnath, Sashi, et al.
Publicado: (2022)

Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll like receptor agonists
por: Triozzi, Pierre L., et al.
Publicado: (2011)

A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
por: Leigh, Nicholas D., et al.
Publicado: (2014)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance
por: Zhang, Yumin, et al.
Publicado: (2022)

Photodynamic therapy exploiting the anti-tumor activity of mannose-conjugated chlorin e6 reduced M2-like tumor-associated macrophages
por: Soyama, Tatsuki, et al.
Publicado: (2021)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist
por: Hu, Zhiqiang, et al.
Publicado: (2013)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
por: He, Mi, et al.
Publicado: (2022)

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
por: Dovedi, Simon J., et al.
Publicado: (2016)

Breast cancer vaccines: maximizing peptide-based vaccines by regulatory T cell depletion and toll-like receptor 9 activation
por: Nava-Parada, Pilar, et al.
Publicado: (2007)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Toll-Like Receptors (TLRs): The Role in Tumor Progression
por: Shcheblyakov, D.V., et al.
Publicado: (2010)

The role of toll-like receptor 4 in tumor microenvironment
por: Li, Jing, et al.
Publicado: (2017)

The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
por: Cen, Xiaohong, et al.
Publicado: (2018)

Roles of Toll-Like Receptor 3 in Human Tumors
por: Zheng, Xin, et al.
Publicado: (2021)

The phosphoproteome of toll-like receptor-activated macrophages
por: Weintz, Gabriele, et al.
Publicado: (2010)

Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer
por: Cai, Xin-Jun, et al.
Publicado: (2017)

A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
por: Nahimana, A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rgtq30jb9g3g3k24rmg3hut8i6